老年肺癌转移患者的综合管理策略

doi:10.3969/j.issn.1003-9198.2026.10.004

摘要/Abstract

摘要： 随着人口老龄化进程加快,老年肺癌患者数量持续增加,其转移性疾病的临床管理面临严峻挑战。受器官功能储备下降、多病共存及免疫衰老影响,老年患者在肿瘤转移特征、并发症谱及治疗耐受性方面独具特点。脑、骨及肝脏是常见转移部位,其中脑转移和肝转移预后较差。脑转移、心血管事件、血栓栓塞、营养不良及跌倒等并发症进一步增加治疗老年肺癌患者的复杂性和死亡风险。近年来,靶向治疗和免疫治疗改善了部分老年患者的生存获益,但高龄患者的安全性和疗效仍需进一步优化。本文围绕老年肺癌转移特征、常见并发症及治疗策略进行综述,旨在为个体化综合管理提供参考。

关键词: 老年人, 肺癌, 转移, 综合管理

Abstract: With the rapid aging of the global population, the number of elderly patients with lung cancer continues to increase, posing considerable challenges to the management of metastatic disease. Owing to reduced physiological reserve, multiple comorbidities, and immunosenescence, elderly patients exhibit distinct characteristics in metastatic patterns, complication profiles, and treatment tolerance. The brain, bone, and liver are the most common sites of metastasis, brain and liver metastases associated with particularly poor prognosis. Complications including brain metastasis, cardiovascular disease, thromboembolic events, malnutrition, and falls further increase treatment complexity and mortality risk. In recent years, targeted therapy and immunotherapy have improved survival in selected elderly patients; however, the safety and efficacy balance in the very elderly populations remains to be optimized. This review summarizes the metastatic features, major complications, and therapeutic strategies in older adults with lung cancer, aiming to provide a reference for individualized, comprehensive management.

Key words: aged, lung cancer, metastasis, comprehensive management

中图分类号:

R734.2

殷诗媛, 徐同鹏. 老年肺癌转移患者的综合管理策略[J]. 实用老年医学, 2026, 40(10): 992-996.

YIN Shiyuan, XU Tongpeng. Comprehensive management strategies for elderly patients with metastatic lung cancer[J]. Practical Geriatrics, 2026, 40(10): 992-996.

参考文献

[1] REMON J, ALDEA M, BESSE B, et al. Small cell lung cancer: a slightly less orphan disease after immunotherapy[J]. Ann Oncol, 2021, 32(6): 698-709.
[2] GOMES F, TAY R, CHIRAMEL J, et al. The role of targeted agents and immunotherapy in older patients with non-small cell lung cancer[J]. Drugs Aging, 2018, 35(9): 819-834.
[3] ZAHED H, FENG X, SHEIKH M, et al. Age at diagnosis for lung, colon, breast and prostate cancers: an international comparative study[J]. Int J Cancer, 2024, 154(1): 28-40.
[4] GAJRA A, ALI AKBAR S, DIN N U. Management of lung cancer in the elderly[J]. Clin Geriatr Med, 2016, 32(1): 81-95.
[5] LOSANNO T, GRIDELLI C. First-line treatment of metastatic non-small cell lung cancer in the elderly[J]. Curr Oncol Rep, 2021, 23(10): 119.
[6] NAKAZAWA K, KURISHIMA K, TAMURA T, et al. Specific organ metastases and survival in small cell lung cancer[J]. Oncol Lett, 2012, 4(4): 617-620.
[7] WANG S, TANG W, JIN F, et al. Comprehensive analysis of lung cancer metastasis: sites, rates, survival, and risk factors-a systematic review and meta-analysis[J]. Clin Respir J, 2025, 19(7): e70107.
[8] DONG Y, ZHOU S, LI J, et al. Distant metastatic patterns in young and old non-small cell lung cancer patients: a dose-response analysis based on SEER population[J]. Heliyon, 2024, 10(17): e36657.
[9] SOCHA J, RYCHTER A, KEPKA L. Management of brain metastases in elderly patients with lung cancer[J]. J Thorac Dis, 2021, 13(5): 3295-3307.
[10] MUHANDIRAMGE J, ZALCBERG J, WARNER E, et al. Cardiovascular disease and stroke following cancer and cancer treatment in older adults[J].Cancer, 2024, 130(23): 4138-4148.
[11] HONG H, WANG Q, LI J, et al. Aging, cancer and immunity[J]. J Cancer, 2019, 10(13): 3021-3027.
[12] THAPA R, GUPTA S, GUPTA G, et al. Epithelial-mesenchymal transition to mitigate age-related progression in lung cancer[J]. Ageing Res Rev, 2024, 102: 102576.
[13] ZENKE Y, HAKOZAKI T, NAKAHARA Y, et al. Medical management of older patients with lung cancer[J]. Jpn J Clin Oncol, 2022, 52(10): 1082-1088.
[14] GOMES F, WONG M, BATTISTI N M L, et al. Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper[J]. Br J Cancer, 2020, 123(6): 874-884.
[15] PATEL A A H, DZANAN J J, ALI K X, et al. Ageing promotes metastasis via activation of the integrated stress response[J]. Nature, 2026, 652(8112): 1339-1348.
[16] GU Y, ZHANG J, ZHOU Z, et al. Metastasis patterns and prognosis of octogenarians with NSCLC: a population-based study[J]. Aging Dis, 2020, 11(1): 82-92.
[17] ZOU J, GUO S, XIONG M T, et al. Ageing as key factor for distant metastasis patterns and prognosis in patients with extensive-stage Small Cell Lung Cancer[J]. J Cancer, 2021, 12(6): 1575-1582.
[18] LAMBA N, KEARNEY R B, CATALANO P J, et al. Population-based estimates of survival among elderly patients with brain metastases[J]. Neuro Oncol, 2021, 23(4): 661-676.
[19] 中国医师协会肿瘤医师分会, 中国医疗保健国际交流促进会肿瘤内科分会. 肺癌脑转移中国治疗指南(2021年版)[J]. 中华肿瘤杂志, 2021, 43(3): 269-281.
[20] MAHASHABDE R V, BHATTI S A, MARTIN B C, et al. Survival outcomes of immune checkpoint inhibitors in conjunction with cranial radiation for older adults with non-small cell lung cancer and synchronous brain metastasis[J]. Curr Oncol, 2025, 32(9): 499.
[21] RIIHIMÄKI M, HEMMINKI A, FALLAH M, et al. Metastatic sites and survival in lung cancer[J]. Lung Cancer, 2014, 86(1): 78-84.
[22] QIN B D, JIAO X D, LIU J, et al. The effect of liver metastasis on efficacy of immunotherapy plus chemotherapy in advanced lung cancer[J]. Crit Rev Oncol Hematol, 2020, 147: 102893.
[23] SITTHIDEATPHAIBOON P, SIMSEEKEAW P, TEERAPAKPINYO C, et al. Presence of liver metastasis correlated with high tumor abundance and indicated adverse prognostic feature in EGFR mutation non-small-cell lung cancer patients[J]. Sci Rep, 2025, 15(1): 165.
[24] DAI Y, FEI J. Addressing unmet needs in the management of small cell lung cancer: treatment of brain metastases, quality of life, and the role of real-world evidence[J]. Curr Treat Options Oncol, 2026, 27(1): 25.
[25] QIN Y, LIANG X, SUN X, et al. Clinical characteristics and prognosis of thromboembolism in elderly patients with stage IV lung cancer[J]. Geriatr Gerontol Int, 2026, 26(1): e70325.
[26] ALMURADOVA E, MENEKSE S. Survival outcomes and prognostic nutritional index in very elderly small-cell lung cancer patients: importance of active treatment and nutritional support[J]. Aging Male, 2023, 26(1): 2251573.
[27] JIANG S, YANG A, YANG F, et al. The Geriatric Nutritional Risk Index as a prognostic factor in patients treated with immune checkpoint inhibitors with non-small-cell lung cancer[J]. J Thorac Dis, 2024, 16(8): 5222-5237.
[28] GENDARME S, ZEBACHI S, CORRE R, et al. Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic non-small-cell lung cancer: a secondary analysis of ESOGIA-GFPC-GECP 08-02 study[J]. J Geriatr Oncol, 2024, 15(6): 101506.
[29] WANG Q, HAN X, ZHANG J, et al. Construction of a risk prediction model for falls in elderly lung cancer patients with sarcopenia[J]. Front Oncol, 2025, 15: 1533368.
[30] COUDERC A L, BOUHNIK A D, REY D, et al. Quality of life in older French long-term lung cancer survivors: VICAN5 national survey[J]. Lung Cancer, 2023, 180: 107197.
[31] QUOIX E. Therapeutic options in older patients with metastatic non-small cell lung cancer[J]. Ther Adv Med Oncol, 2012, 4(5): 247-254.
[32] AHMED Z, KENNEDY K, SUBRAMANIAN J. The role for chemotherapy in 80 years and older patients with metastatic non-small cell lung cancer: a National Cancer Database analysis[J]. Lung Cancer, 2021, 154: 62-68.
[33] PELIZZARI G, CORTIULA F, GIAVARRA M, et al. Platinum-based chemotherapy in older patients with non-small cell lung cancer: what to expect in the real world[J]. Drugs Aging, 2020, 37(9): 677-689.
[34] ROVIELLO G, ZANOTTI L, CAPPELLETTI M R, et al. Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?[J]. Clin Exp Med, 2018, 18(1): 15-20.
[35] BRUECKL W M, RECK M, SCHÄFER H, et al. Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: a subset analysis of the non-interventional GIDEON study[J]. J Geriatr Oncol, 2023, 14(1): 101394.
[36] DO T A, NGUYEN H T T, PHAM P C, et al. Efficacy and tolerance of first-line afatinib in elderly NSCLC patients with EGFR mutations in Vietnam: a multicenter real-world study[J]. Asian Pac J Cancer Prev, 2024, 25(10): 3567-3576.
[37] CERBONE L, BENITEZ J C, PLANCHARD D, et al. An overview of osimertinib as a treatment of non-small cell lung cancer(NSCLC): an update[J]. Expert Opin Pharmacother, 2021, 22(7): 809-819.
[38] LANDRE T, CHOUAÏD C, SADAOUI N, et al. Clinical benefit of anti-PD-1/PD-L1 plus chemotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic non-small cell lung cancer(NSCLC)[J]. J Chemother, 2024, 36(8): 675-681.[39]SUN Y M, WANG Y, SUN X X, et al. Clinical efficacy of immune checkpoint inhibitors in older non-small-cell lung cancer patients: a meta-analysis[J]. Front Oncol, 2020, 10: 558454.
[40] MARUR S, SINGH H, MISHRA-KALYANI P, et al. FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies[J]. Semin Oncol, 2018, 45(4): 220-225.
[41] CORRE R, DECROISETTE C, AULIAC J B, et al. First-line pembrolizumab efficacy in octogenarians with NSCLCs expressing ≥ 50% PD-L1(ESCKEYP GFPC 05-2018)[J]. Clin Lung Cancer, 2025, 26(4): 331-337.
[42] RONG Y, BENTLEY J P, BHATTACHARYA K, et al. Incidence and risk factors of immune-related adverse events induced by immune checkpoint inhibitors among older adults with non-small cell lung cancer[J].Cancer Med, 2024, 13(1): e6879.
[43] RAMOS M J, MENDES A S, ROMÃO R, et al. Immunotherapy in elderly patients—single-center experience[J]. Cancers, 2023, 16(1): 145.
[44] NIPP R D, GREER J A, EL-JAWAHRI A, et al. Age and gender moderate the impact of early palliative care in metastatic non-small cell lung cancer[J]. Oncologist, 2016, 21(1): 119-126.
[45] MORITA T, KURIYA M, MIYASHITA M, et al. Symptom burden and achievement of good death of elderly cancer patients[J]. J Palliat Med, 2014, 17(8): 887-893.